Tesamorelin: Research Overview

The short version

Tesamorelin is a synthetic analog of growth hormone-releasing hormone — the signaling peptide that tells the pituitary to release GH — modified to last longer in the bloodstream than the natural molecule. Unlike the other compounds on this desk, it has been through rigorous Phase 3 randomized clinical trials and received FDA approval. That approval, granted in 2010, is narrow and specific: reducing excess abdominal fat in adults with HIV infection who have developed antiretroviral drug-related lipodystrophy (a metabolic side effect involving abnormal fat redistribution). Every other use — visceral fat reduction in people without HIV, anti-aging, cognitive enhancement, general body composition — is off-label and investigational.

The controlled-trial evidence for the approved indication is real and meaningful: tesamorelin consistently reduces visceral adipose tissue and hepatic fat in HIV populations in randomized trials. The limits of that evidence matter equally: the trials were conducted in HIV-positive adults, the fat returns when the compound is stopped, and long-term oncologic safety data are limited. This page follows the evidence where it goes.

What it is

Tesamorelin is a synthetic 44-amino-acid peptide that mirrors the full sequence of human GHRH(1-44)-NH2, bearing a trans-3-hexenoic acid group conjugated to the N-terminus. That N-terminal modification confers resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending plasma stability relative to native GHRH while preserving the full-length receptor interaction that shorter fragments like sermorelin do not replicate.

It is known in the development literature by the designation TH9507, and it is supplied clinically as the acetate salt. The FDA-approved product was cleared under NDA 022505 in November 2010 for the specific indication of reducing excess abdominal fat in HIV-infected adults with lipodystrophy ^[13].

The trademark names for approved tesamorelin products are not used on this desk. All content uses the generic compound name.

Research-grade tesamorelin is also available from laboratory supply channels for non-clinical research use, without the purity and potency oversight of the pharmaceutical product.

How it works

Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells and activates the Gs/adenylyl-cyclase/cAMP/PKA cascade, stimulating synthesis and pulsatile secretion of endogenous growth hormone. The resulting GH drives hepatic production of IGF-1 and promotes lipolysis — the breakdown of stored fat — preferentially in visceral adipose tissue ^[1][13].

Because it amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH, its metabolic profile differs from that of recombinant GH in ways that have interested researchers: pulsatility is preserved, and feedback suppression through somatostatin remains intact.

A study of 13 healthy men treated with tesamorelin for two weeks found mean overnight GH increased significantly (P=0.004) and IGF-1 rose by 181 micrograms/liter (P<0.0001), while neither fasting glucose (P=0.93) nor insulin-stimulated glucose uptake (P=0.61) was significantly affected — an early signal that short-term GH-axis stimulation did not impair insulin sensitivity in this healthy-male sample ^[15]. That is a two-week study in healthy men, not a long-term safety finding, and other evidence suggests glucose monitoring remains warranted in people with existing dysglycemia.

What the research shows

The evidence base for tesamorelin is the strongest on this desk, concentrated in its approved indication.

A 2026 meta-analysis pooled five randomized controlled trials in HIV-associated lipodystrophy and found tesamorelin reduced visceral adipose tissue by a mean of 27.71 cm² (95% CI: -38.37 to -17.06; P<0.001), trunk fat by 1.18 kg, and hepatic fat fraction by 4.28 percentage points, while increasing lean body mass by 1.42 kg — all statistically significant, without serious adverse events ^[12].

A 2014 JAMA randomized trial in 50 antiretroviral-treated HIV adults found the treatment effect on visceral fat was -42 cm² (P=0.005) and on hepatic lipid was a net -2.9 percentage points (P=0.003) ^[14]. A longer-term program at 52 weeks found a sustained -18% reduction in VAT (P<0.001 vs baseline), though visceral fat reaccumulated after the compound was discontinued — and changes in glucose parameters over the 52-week period were not clinically significant ^[16].

The NIH LiverTox monograph rates tesamorelin with a likelihood score of E (unlikely cause of clinically apparent liver injury) and notes no attributable liver-injury cases and no de novo serum-enzyme elevations in the trials ^[13].

Outside the HIV lipodystrophy context, the evidence gets thinner. An important earlier RCT tested a GHRH analog in 152 older adults (including 66 with mild cognitive impairment) and found a statistically favorable effect on cognition at 20 weeks (P=0.03), with executive function improving (P=0.005), IGF-1 rising 117%, and body fat falling 7.4% ^[2]. That trial is frequently cited in discussions of GHRH analogs and aging, and it is informative — but it used a GHRH analog in a cognitive-impairment trial, not in general healthy aging, and subsequent data in HIV populations did not replicate significant neurocognitive improvement [the controversies section notes this unresolved picture]. For non-HIV populations, large confirmatory RCTs do not exist.

Reported effects, cautions, and safety

Unlike sermorelin and CJC-1295, there is a substantial controlled-trial adverse-event record for tesamorelin — because the approved compound was tested in Phase 3. The clinical safety picture from the trials is: injection-site reactions (redness, pain, induration) and modest rises in IGF-1 are the most common documented adverse effects. Across the 52-week program, glucose changes were not clinically significant and no excess malignancy signal emerged over that timeframe — a limited window for long-term oncologic safety ^[16].

Clinically meaningful safety cautions from the literature:

• Approved indication is narrow: Every use outside HIV-associated lipodystrophy is off-label and lacks Phase 3 evidence ^[13].
• Visceral fat reaccumulates on discontinuation: Benefits are contingent on continued use. This is not a one-course correction ^[16].
• GH and IGF-1 elevation — oncologic risk: Active malignancy is a labeled contraindication for tesamorelin. Long-term cancer-risk data beyond 52-week trials do not exist; IGF-1 is mitogenic, and the theoretical concern is acknowledged ^[12][13].
• Glucose monitoring in dysglycemia: Though a dedicated glucose study and the 52-week trials showed no significant HbA1c change, GH is glucose-sparing and individual responses in predisposed people can vary. Monitoring is warranted for people with prediabetes ^[15][16].
• Generalizability to non-HIV populations: All Phase 3 evidence was collected in HIV-positive adults on antiretroviral therapy. Whether the efficacy and safety profile translates to non-HIV populations with visceral obesity is mechanistically plausible but not established by large RCTs.
• Injection-only administration: The compound has no oral bioavailability and requires subcutaneous administration.
• Anti-doping prohibition: Tesamorelin is prohibited in sport under WADA Prohibited List category S2 (peptide hormones, growth factors, related substances and mimetics), in- and out-of-competition.

Where it fits in the Growth Hormone Axis theme

Tesamorelin is the clinical anchor of this desk. It represents the GHRH-analog research path where the Phase 3 work was actually done — and where the evidence both confirms the mechanism (GHRH stimulation reduces visceral fat) and defines its limits (approved for one population, effects reverse on discontinuation, long-term data remain limited).

Its presence here alongside sermorelin and CJC-1295 is useful for exactly that reason: it lets you see what a fully developed GH-axis program looks like when the trials are completed and a regulator reviews them. The approved indication is narrow. The evidence within that indication is real. Everything else is extrapolation or hypothesis.

Read the compare page to see how the three compounds differ across mechanism, evidence maturity, and regulatory status, or return to Sermorelin or CJC-1295.